the outcome of treatment with recombinant tissue plasminogen activator in acute ischemic stroke

Background: thrombolytic therapy is the recommended treatment of acute ischemic stroke. it is crucial to evaluate the treatment results with recombinant tissue plasminogen activator (r-tpa) in patients with acute stroke. objectives: this study aimed to evaluate treatment outcomes with r-tpa in patients with acute stroke in a referral stroke center in iran. materials & methods: in this retrospective study, 87 patients with symptoms of acute stroke were examined. they were referred to a stroke center in gilan province, iran, from june 2016 to april 2020 and received r-tpa (0.9 mg/kg). demographic information, the time interval between the onset of symptoms and r-tpa administration, complications, and national institutes of health stroke scale (nihss) upon arrival and discharge and death of patients were extracted from their hospital files. the paired t-test, independent t-test, and pearson correlation test were used to compare variables using ibm spss for windows version 20.0 (ibm corp., armonk, ny, usa). results: the mean±sd of nihss reduced from 14.7±6.4 to 8.9±7.6 (p<0.001). the most common complication was intracerebral hemorrhage (ich) (12.6%). the hospital mortality rate was 23%. ich occurred among 40% (n=8) of those who expired, and 4.47% (n=3) of them survived, and this difference was significant (p<0.001). conclusion: the recovery with r-tpa administration in the stroke center was acceptable. mortality and ich occurrence rates were higher than other non-iranian studies. it seems that we should change the case selection criteria and prescription dose to achieve better results of treatment with tpa.